Trials
2 active
4 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CAM2029 (octreotide subcutaneous depot) 20 mg will be administered every 2 weeks as a subcutaneous injection”In the company’s words, NCT05050942 on ClinicalTrials.gov
- Main trialPhase 3
- “The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.”In the company’s words, NCT05050942 on ClinicalTrials.gov
- Other names
- octreotide subcutaneous depot
Other drugs for Gastro-enteropancreatic Neuroendocrine Tumor
- RYZ101RayzeBio, Inc. · Phase 3
- 177Lu-edotreotide PRRTITM Solucin GmbH · Phase 3
- VMT-α-NETPerspective Therapeutics · Phase 1/2
- CVM-1118TaiRx, Inc. · Phase 2
- Lu-DOTA-TATENovartis Pharmaceuticals · Phase 2
- RYZ401RayzeBio, Inc. · Phase 1
Coming up1
- NovPhase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Nov 2026 | A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET | |
| Phase 2/3Active, not recruiting | 5 Feb 2025 | A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD | |
| Phase 3Completed | 2 May 2023 | A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly | |
| Phase 3Completed | 24 Apr 2025 | A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026